CD274 and neoplasm: They collected a large number of patients with uroepithelial carcinoma from patients treated with an anti-PD-L1 drug (atezolizumab) and found that a good immunotherapy response was associated with a CD8+ T-effector cell phenotype and tumor mutational load (TMB).